The pivotal trial for Neurogene's Rett syndrome gene therapy makes use of baseline controls and a rigorous endpoint that ...

Company announcement - No. 15 / 2025 Zealand Pharma announces positive topline results from 28-week Phase 1b trial with GLP-1/GLP-2 receptor dual agonist dapiglutide Body weight reductions of a mean ...

Compass Pathways' Phase 3 COMP-360 data met primary endpoints but disappointed vs analyst expectations. See why investors ...

More than two-thirds of clinical trials fail to meet original patient enrolment targets, 85% fail to retain enough patients, and the average dropout rate across all trials is 30%. 1 Yet the ...

Monotherapy efficacy and safety profile provided backbone for clinical development strategy in 1L combination with nivolumab plus chemotherapy ...

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for value-driven solutions.

Maertens reported relationships with F2G, Cidara, Pfizer, Gilead, MSD, Takeda, Mundipharma, Basilea, and Shionogi. Co-authors ...

CCCC's valuation is unjustifiably low, trading at half its liquidity despite a promising pipeline and no imminent cash crisis. Click here to read my analysis.

PR Newswire ATLANTA, June 27, 2025 ATLANTA, June 27, 2025 /PRNewswire/ -- UCB, a global biopharmaceutical company, today announced that the Phase 3 study investigating the safety ...

During a live event, Hari Deshpande, MD, and participants discussed the DeFi trial and the management of nirogacestat in ...

Researchers have found in a phase IIb study that investigational antifungal olorofim demonstrated efficacy in 29% of patients ...

As generic versions of AstraZeneca’s blockbuster drug ticagrelor prepare to enter the market, The BMJ raises fresh concerns over the integrity of the clinical trials that underpinned its approval.